CLINICAL TRIALS PROFILE FOR SETIPIPRANT
✉ Email this page to a colleague
Clinical Trials for Setipiprant
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT01225315 ↗ | Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma | Completed | Actelion | Phase 2 | This study will assess the efficacy and safety of ACT-129968 in subjects with partly controlled asthma on reliever therapy only. |
| NCT01225315 ↗ | Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma | Completed | Idorsia Pharmaceuticals Ltd. | Phase 2 | This study will assess the efficacy and safety of ACT-129968 in subjects with partly controlled asthma on reliever therapy only. |
| NCT01484119 ↗ | Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis | Completed | Actelion | Phase 3 | This study will assess the efficacy and safety of ACT-129968 in adolescent, adult and elderly patients with seasonal allergic rhinitis, due to mountain cedar pollen. |
| NCT01484119 ↗ | Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis | Completed | Idorsia Pharmaceuticals Ltd. | Phase 3 | This study will assess the efficacy and safety of ACT-129968 in adolescent, adult and elderly patients with seasonal allergic rhinitis, due to mountain cedar pollen. |
| NCT02381496 ↗ | A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968) | Completed | Actelion | Phase 1 | This is a three-part study to assess the tolerability, safety, pharmacodynamics, and pharmacokinetics of ascending single doses (including food interaction) of ACT-453859 in healthy male subjects, of ascending multiple doses of ACT-453859 in healthy male and female subjects, and of multiple doses of setipiprant (ACT-129968) in healthy male and female subjects. |
| NCT02381496 ↗ | A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968) | Completed | Idorsia Pharmaceuticals Ltd. | Phase 1 | This is a three-part study to assess the tolerability, safety, pharmacodynamics, and pharmacokinetics of ascending single doses (including food interaction) of ACT-453859 in healthy male subjects, of ascending multiple doses of ACT-453859 in healthy male and female subjects, and of multiple doses of setipiprant (ACT-129968) in healthy male and female subjects. |
| NCT02781311 ↗ | A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males | Completed | Allergan | Phase 2 | This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Setipiprant
Condition Name
Clinical Trial Locations for Setipiprant
Trials by Country
Clinical Trial Progress for Setipiprant
Clinical Trial Phase
Clinical Trial Sponsors for Setipiprant
Sponsor Name
